Tuesday, December 24, 2024
spot_img
spot_img
HomeNewsBusiness WireSpotSee Acquires Biosynergy, Inc.

SpotSee Acquires Biosynergy, Inc.

Acquisition will grow SpotSee’s presence in life sciences industry

DALLAS–(BUSINESS WIRE)–SpotSee®, a global leader in condition-indicating solutions that protect life sciences products against damage and ensure supply chain integrity, has finalized its acquisition of the assets of Biosynergy, Inc., a manufacturer of medical devices primarily used to monitor the core temperature of red blood cells.

“This acquisition enables SpotSee to strengthen our mission of reducing damage to products through both the supply and cold chain by adding blood temperature monitoring to our large and growing life science segment,” said Tony Fonk, CEO, SpotSee. “The Biosynergy HemoTemp® brand is a market leader in blood bag monitoring that protects patients from receiving blood that has been exposed to excessive temperature. Its targeted focus and reputation of success makes it a great addition to our temperature-indicating solutions.”

Biosynergy’s HemoTemp brand devices are FDA validated and monitor blood bags to irreversibly indicate if the blood’s core temperature has exceeded 10 degrees Celsius. If blood exceeds 10 degrees Celsius, it should not be used in patients, giving medical professionals an accurate tool to ensure blood is kept at the correct temperature. Additionally, the device contains reversible indicators to show medical professionals if the blood temperature is increasing or decreasing. The device is currently used in major hospital systems and blood labs throughout North America. SpotSee plans to grow the product line geographically through its global distribution and reseller network of over 2,000 partners.

Biosynergy’s products will add to SpotSee’s extensive life-sciences portfolio of products used for monitoring the condition of vaccines, pharmaceuticals, biologics, specimens, blood, diagnostics, and medical devices through globally recognized brands such as WarmMark®, ColdMark®, Thermostrip®, ShockWatch® and Briteline® Drug Testing Strips. SpotSee plans to leverage the Biosynergy technology to expand into blood plasma monitoring.

“SpotSee is the ideal owner for the next generation of Biosynergy and its technology,” said Fred Suzuki, CEO, Biosynergy. “Their global sales, marketing and distribution network combined with manufacturing scale will help the HemoTemp® brand protect blood recipients throughout the world.”

To learn more about SpotSee’s temperature-monitoring capabilities, visit: http://www.biosynergyinc.com/.

About SpotSee

A global leader in condition-indicating solutions, SpotSee helps customers spot and see changing conditions to protect life sciences and ensure supply chain integrity. SpotSee provides connected, visual, mechanical, and chemical solutions that enable over 4,500 customers and partners in 62 countries to detect changes in the condition of everything from vaccines to spaceships as they travel through global supply chains. SpotSee’s solutions include temperature, impact, tilt, vibration, humidity, and liquid detection monitoring devices, available via visual, RFID, QR Code, BLE, cellular or satellite connection. Its products such as WarmMark, ColdMark, ThermoStrip, BriteLine, ShockWatch and TiltWatch are widely used in the life sciences, energy, transportation, aerospace, defense, food, manufacturing, and consumer products sectors. The company is headquartered in Dallas, TX and operates 6 manufacturing facilities in Texas, Illinois, Mexico and the United Kingdom. For more information, visit www.spotsee.io.

About Biosynergy, Inc.

Biosynergy, Inc. has over 40 years’ experience in the time/temperature and quality control industries, manufacturing and distributing disposable temperature monitoring indicators and devices. The company maintains complete records in manufacturing and quality assurance testing on all its products in compliance with Food and Drug Administration (FDA) regulations. All products are manufactured according to “Good Manufacturing Practices” (GMP) for medical devices.

Contacts

Media Contact
Elle Collazo

Mod Op for SpotSee

elle.collazo@modop.com

spot_img
RELATED ARTICLES
spot_img
spot_img
spot_img

Caribbean News

Central Bank of Trinidad and Tobago: Monetary policy report

November 2024 VOLUME XXVI NUMBER 2 PORT- OF- SPAIN, Trinidad - The Central Bank of Trinidad and Tobago conducts monetary policy geared towards the...

Global News

Taiwan monetary policy: December 2024

By FocusEconomics Taiwan Central Bank leaves rates unchanged in December. Latest bank decision: At its meeting on 19 December, Taiwan’s Central Bank decided to keep the discount...